PubMed · 14325488
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
J W HAMPTON. 1965. CHRISTMAS FACTOR.. https://pubmed.ncbi.nlm.nih.gov/14325488/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
We have synthesized a new green fluorescent dopant C-545P having incorporated five strategically placed "methyl" steric spacers on the julolidyl ring system. C-545P has good thermal properties and photostability, and when fabricated as a dopant in an Alq(3)-hosted OLED device, it shows notable improvement in luminance efficiency and is more resistant to concentration quenching than C-545T, particularly in the doping concentration range between 1 and 2% v/v, while achieving comparable device stability. [structure: see text]
Explore the source record for details and available documents.
Patients with paroxysmal atrial fibrillation have a risk of thromboembolic complications probably equivalent to those with permanent atrial fibrillation. Patients with a previous cerebral infarction, hypertension, age above 65, diabetes, previous myocardial infarction, reduced left ventricular function, heart failure or enlarged left atrium with or without a visible thrombus are especially prone to thromboembolic complications. International guidelines recommend anticoagulation therapy with warfarin to INR levels between 2.0-3.0 for the majority of patients with atrial fibrillation. Acetylsalicylic acid provides inferior protection and can only be recommended for a selected subpopulation of patients. Patients with atrial fibrillation who convert spontaneously or after medical or electrical treatment, should have low molecular weight heparin administered prior to conversion and warfarin for at least four weeks after successful conversion. The rationale for choosing a treatment strategy in conflict with recommended guidelines should appear in writing in the patient's file in any individual case.